Add to ORKGcan safely reduce the risk of vision loss in patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD). Design: Two multicenter, double-masked, placebo-controlled, randomized clinical trials. Setting: Twenty-two ophthalmology practices in Eu-rope and North America. Participants:Patients with subfoveal CNV lesions caused by AMD measuring 5400 µm or less in greatest linear di-mension with evidence of classic CNV and best-corrected visual acuity of approximately 20/40 to 20/200. Methods: Six hundred nine patients were randomly as-signed (2:1) to verteporfin (6 mg per square meter of body surface area) or placebo (5 % dextrose in water) admin-istered via intravenous infusion of 30 mL over 10 min
Objective: To determine the long-term effect of photodynamic therapy (PDT) with verteporfin for age-...
Choroidal neovascularization in the macula is a major cause of visual disability in developed countr...
OBJECTIVES: To evaluate safety and short-term visual acuity and fluorescein angiographic effects of ...
excision. The TAP study (Treatment of AMD with PDT) involving 609 patients at 22 centres in the USA ...
To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfo...
OBJECTIVE: To evaluate the safety and short-term visual and fluorescein angiographic effects of a si...
AIM: To assess the safety and efficacy of the combined treatment of reduced-fluence verteporfin phot...
PURPOSE: To determine if photodynamic therapy with verteporfin (Visudyne; Novartis AG, Bulach, Switz...
OBJECTIVE: To evaluate short-term safety and the effects on visual acuity and fluorescein angiograph...
BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascul...
To report vision and safety outcomes from an extension of a 2-year investigation evaluating vertepor...
Age-related macular degeneration (AMD) is the most common cause of visual disability and blindness i...
Purpose: To review and discuss the available treatments for choroidal neovascularization (CNV) due t...
PURPOSE: To evaluate the 12-month visual outcome of photodynamic therapy with verteporfin (PDT-V) fo...
BackgroundTo evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients ...
Objective: To determine the long-term effect of photodynamic therapy (PDT) with verteporfin for age-...
Choroidal neovascularization in the macula is a major cause of visual disability in developed countr...
OBJECTIVES: To evaluate safety and short-term visual acuity and fluorescein angiographic effects of ...
excision. The TAP study (Treatment of AMD with PDT) involving 609 patients at 22 centres in the USA ...
To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfo...
OBJECTIVE: To evaluate the safety and short-term visual and fluorescein angiographic effects of a si...
AIM: To assess the safety and efficacy of the combined treatment of reduced-fluence verteporfin phot...
PURPOSE: To determine if photodynamic therapy with verteporfin (Visudyne; Novartis AG, Bulach, Switz...
OBJECTIVE: To evaluate short-term safety and the effects on visual acuity and fluorescein angiograph...
BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascul...
To report vision and safety outcomes from an extension of a 2-year investigation evaluating vertepor...
Age-related macular degeneration (AMD) is the most common cause of visual disability and blindness i...
Purpose: To review and discuss the available treatments for choroidal neovascularization (CNV) due t...
PURPOSE: To evaluate the 12-month visual outcome of photodynamic therapy with verteporfin (PDT-V) fo...
BackgroundTo evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients ...
Objective: To determine the long-term effect of photodynamic therapy (PDT) with verteporfin for age-...
Choroidal neovascularization in the macula is a major cause of visual disability in developed countr...
OBJECTIVES: To evaluate safety and short-term visual acuity and fluorescein angiographic effects of ...